Journal
HYPERTENSION
Volume 47, Issue 5, Pages 887-893Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.HYP.0000215207.54689.31
Keywords
heart failure; remodeling; endothelial growth factors; hypertrophy
Categories
Funding
- NHLBI NIH HHS [P01 HL066957, HL66957, R01 HL077774-03, R01 HL077774, HL77774] Funding Source: Medline
- NIAMS NIH HHS [R01 AR040197, AR40197] Funding Source: Medline
- NIA NIH HHS [R01 AG015052-04, R01 AG015052, AG15052, R37 AG015052] Funding Source: Medline
Ask authors/readers for more resources
Cardiac hypertrophy is associated with upregulation of vascular endothelial growth factor ( VEGF) in the myocardium. Here, we evaluated the effects of a decoy VEGF receptor on heart morphology and function to a murine model of pressure overload hypertrophy. Mice were administered adenoviral vector encoding a decoy VEGF receptor (Ad-Flk), and their hearts were subjected to pressure overload by transverse aortic constriction (TAC). Treatment with Ad-Flk led to a net reduction in capillary density in hearts subjected to TAC. Ad-Flk also led to a reduction in TAC-induced cardiac hypertrophy and promoted left ventricle dilatation and a loss in contractile function. Treatment with Ad-Flk markedly increased myocardial fibrosis and collagen gene upregulation. In contrast, Ad-Flk had no effect on any of these parameters in sham-treated mice. Administration of a VEGF trap reagent diminished pressure overload cardiac hypertrophy and promoted the progression to heart failure but had no effect on sham-treated animals. These findings suggest that VEGF is required to maintain myocardial capillary density and that reductions in the vascular bed are associated with the transition from compensatory hypertrophy to failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available